05/17/22 7:00 AMNasdaq : SLGL conferenceslow floatSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment ConferenceSol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin diseases, today announced that that theRHEA-AIneutral
05/13/22 7:00 AMNasdaq : SLGL earningslow floatSol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate UpdateFDA approval for EPSOLAY ® (benzoyl peroxide, cream, 5%) represents Sol-Gel’s second approved product within less than a year ; EPSOLAY is patent protected until 2040 Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launch ed in the U.S. market in April for the topicalRHEA-AIvery positive
04/25/22 7:00 AMNasdaq : SLGL fda approvallow floatSol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®EPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel’s proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma set to commercialize EPSOLAY in the U.S. under exclusive license NESS ZIONA, Israel and ZUG,RHEA-AIvery positive
04/14/22 8:30 AMNasdaq : SLGL low floatSol-Gel Technologies Announces the Commercial Availability of TWYNEO®TWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acne Sol-Gel’s U.S. commercialization partner, Galderma, launched TWYNEO ® in the U.S. at the Annual Meeting of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO is now available forRHEA-AIneutral
03/30/22 7:00 AMNasdaq : SLGL earningslow floatSol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate DevelopmentsGalderma launched TWYNEO ® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022. 2021 revenue of $31.3 million Sol-Gel to receive $21.5 million over 24 months in exchange for the transfer of its rightsRHEA-AIpositive
03/25/22 11:00 AMNasdaq : SLGL low floatSol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MASol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug productsRHEA-AIneutral
12/22/21 4:05 PMNasdaq : SLGL conferenceslow floatSol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare ConferenceSol-Gel Technologies, Ltd. (Nasdaq: SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that theRHEA-AIneutral
12/21/21 7:00 AMNasdaq : SLGL low floatSol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company focused on identifying,RHEA-AIneutral
11/11/21 7:00 AMNasdaq : SLGL earningslow floatSol-Gel Technologies Reports Third Quarter 2021 Financial Results and Highlights Recent Corporate DevelopmentsSol-Gel attains a profitable quarter , reporting total revenues of $ 8.8 million , net income of $1.3 million and EPS of $0. 06 Recently obtained FDA approval of TWYNEO ® trigger s a $ 3.5 million milestone payment from Galderma , and , together with the $4.0 million down payment from Galderma , aRHEA-AIvery positive
11/09/21 7:05 AMNasdaq : SLGL conferenceslow floatSol-Gel Technologies to Present Live at Jefferies London Healthcare ConferenceSol-Gel Technologies, Ltd. (Nasdaq: SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases, today announced that the Company willRHEA-AIneutral